Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Association Between Endogenous Estradiol and Agitation Severity in Alzheimer’s Disease
EF 2025-26
Résumé
Agitation is one of the most challenging symptoms of Alzheimer’s disease (AD), affecting up to 50% of individuals with moderate-to-severe dementia. Agitation is linked to increased cognitive decline, reduced quality of life, and caregiver burden. Current treatments, mainly atypical antipsychotics, are only modestly effective and carry risks such as stroke or death, highlighting the need for safer alternatives. Women make up two-thirds of the AD population and often demonstrate higher rates and greater severity of agitation than men. Biological sex differences, such as hormonal patterns may contribute to these effects, as estradiol (E2), a form of estrogen that supports brain health and serotonin function, decreases abruptly after menopause. Although E2 can influence mood and behaviour, findings are mixed and have not explored if natural E2 levels are linked to agitation in AD. A cross-sectional design will be applied using baseline data from two ongoing clinical trials and a non-agitated comparison group. This study will examine if E2 levels in the blood are associated with agitation severity in 86 persons with moderate-to-severe AD. Standardized agitation scales and factors such as sex, age, and body mass index will be used to estimate E2's contribution. By investigating natural hormone levels, this research clarifies how biological differences shape behavioural symptoms in AD and guides treatment choices that align with an individual's hormone profile. Understanding how hormones influence behaviour can help clinicians improve therapeutic care and reduce caregiver burden. The findings may also support selecting mood-pathway medications such as antidepressants when symptoms appear related to low E2 and serotonin function, rather than relying on atypical antipsychotics.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573262
Name
Adamo Alexandra J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Association Between Endogenous Estradiol and Agitation Severity in Alzheimer’s Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Agitation; Alzheimer’S Disease; Antidepressant Responsiveness; Biological Sex Differences; Estradiol (E2); Estrogen-Mediated Effects; Neuroinflammation; Neuropsychiatric Symptoms; Personalized Medicine; Serotonin Function
Abstract
Agitation is one of the most challenging symptoms of Alzheimer’s disease (AD), affecting up to 50% of individuals with moderate-to-severe dementia. Agitation is linked to increased cognitive decline, reduced quality of life, and caregiver burden. Current treatments, mainly atypical antipsychotics, are only modestly effective and carry risks such as stroke or death, highlighting the need for safer alternatives. Women make up two-thirds of the AD population and often demonstrate higher rates and greater severity of agitation than men. Biological sex differences, such as hormonal patterns may contribute to these effects, as estradiol (E2), a form of estrogen that supports brain health and serotonin function, decreases abruptly after menopause. Although E2 can influence mood and behaviour, findings are mixed and have not explored if natural E2 levels are linked to agitation in AD. A cross-sectional design will be applied using baseline data from two ongoing clinical trials and a non-agitated comparison group. This study will examine if E2 levels in the blood are associated with agitation severity in 86 persons with moderate-to-severe AD. Standardized agitation scales and factors such as sex, age, and body mass index will be used to estimate E2's contribution. By investigating natural hormone levels, this research clarifies how biological differences shape behavioural symptoms in AD and guides treatment choices that align with an individual's hormone profile. Understanding how hormones influence behaviour can help clinicians improve therapeutic care and reduce caregiver burden. The findings may also support selecting mood-pathway medications such as antidepressants when symptoms appear related to low E2 and serotonin function, rather than relying on atypical antipsychotics.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Adamo, Alexandra J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~